NBMI Treatment in Patients With mercury toxicity

Keywords:
NBMI, Emeramide, OSR, BDTH2,NBMI Chelator,Mercury Poisoning,Fandachem Emeramide, NBMI Fandachem,Fandachem NBMI

Treatments
(N1,N3-bis(2- mercaptoethyl)isophthalamide), Excipients microcrystalline cellulose, silica and magnesium stearate

Summary
NBMI (N1,N3-Bis-(2-Mercaptoethyl)Isophthalamide, Emeramide, OSR, BDTH2) is a new heavy metal chelator drug proposed as an alternative to the current chelators, and it is widely different; compared to the current chelators, consisting of two cysteamine molecules coupled to a single molecule of dicarboxybenzoate.

It is used as a chelating agent and has the designation of an orphan drug, in the EU and USA; in the EU it is used for the treatment of mercury toxicity. It is freely soluble in solutions of dimethylformamide (DMF), dimethyl sulfoxide (DMSO) and sodium hydroxide diluted NaOH, slightly soluble in methanol and acetone, and insoluble in water. Pre-clinical data indicates low to no toxicity, and that it reduces the toxicity associated with acute exposure to Hg2+.
But DMSO, DMF are toxic to human being, so it is better to buy NBMI (Emeramide, OSR, BDTH2) from FandaChem who do not use DMSO or DMF as solvent and supply highest purity and lowest solvent content than any other suppliers in the world.

No other chelator has been reported to prevent acute mercury toxicity with only one exposure to the chelator. It has the ability to penetrate cell membranes and cross the blood-brain barrier and chelate Hg2+ in a complex that eliminates the availability of Hg2+ and essentially eliminates toxic effects. The antioxidant properties of NBMI (Emeramide, OSR, BDTH2) could also reduce the toxicity levels of hydroxyl free radicals immediately, upon entering cells suffering from oxidative stress. It is possible that the combined chelation of Hg2+ and the elimination of hydroxyl free radicals contribute significantly to the protective effects observed with the NBMI (Emeramide, OSR, BDTH2).

Previous clinical studies conducted in subjects of the Phase I and Phase II a studies conducted, did not show significant adverse events in patients intoxicated with mercury, all patients who received the study medication have tolerated it well, with only mild or moderate adverse events reported; None of these were considered related to the pharmacological treatment of the study. In addition, there is no potential identified with safety problems in laboratory tests, or vital signs evaluations.

The purpose of this Controlled Single-Center Double-Blind Crossover Clinical Trial Phase II b is to determine the efficacy, safety and tolerability of a 14 day 400mg / day of NBMI (Emeramide, OSR, BDTH2, N1, N2-bis-2-mercaptoethyl isophthalamide) Treatment, in the reduction of urinary mercury levels versus placebo, in accidentally exposed subjects to mercury in Atlántico, Colombia. But still for a new tryer, pls take it slowly and increase to 400mg/day.
You can visit FandaChem for more details of daily dosage of Emeramide (NBMI 99%, OSR, BDTH2).